Results 111 to 120 of about 19,263 (243)

Pretransfusion Testing and Daratumumab: Assessing Interference Risks and Developing Solutions

Global Journal of Transfusion Medicine
Daratumumab is a monoclonal antibody; anti-CD38 is used for the treatment of multiple myeloma and other hematological disorders. Daratumumab, binds to CD 38 on red blood cells (RBCs), interfering with pretransfusion testing. This interference can lead to
Saroj Rajput, Tathagata Chatterjee, Rahul Bhargava, Sanjay Rai   +3 more
doaj   +1 more source

Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey

, 2021
Uroš Markovic, Alessandra Romano, Vittorio Del Fabro, Claudia Bellofiore, Anna Bulla, Marina Parisi, Salvatore Leotta, Massimo Gentile, Clotilde Cangialosi, Iolanda Donatella Vincelli, Giuseppe Mineo, Marco Rossi, Massimo Poidomani, Giuseppina Uccello, Cinzia Maugeri, Donato Mannina, Vanessa Innao, Francesco Di Raimondo, Concetta Conticello   +18 more
openalex   +1 more source

Rapid identification of daratumumab interference with M-protein detection using MALDI-TOF mass spectrometry: a case study involving renal light chain amyloidosis

Practical Laboratory Medicine
Therapeutic monoclonal antibodies (t-mAbs), such as daratumumab (anti-CD38), are increasingly used in plasma cell disorders including systemic AL amyloidosis.
Hou-Long Luo, Anping Xu, Ling Ji
doaj   +1 more source

Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma [PDF]

, 2021
N. Narsipur, Sabrina Bulla, Connie Yoo, Brenda Do, Kyle Tran, Dian Gu, Lixian Zhong, Leslie Wilson   +7 more
openalex   +1 more source

Autologous STEM Cell Collection after Daratumumab, Bortezomib, Thalidomide and Dexamethasone Versus Bortezomib, Thalidomide and Dexamethasone in NEWLY Diagnosed Multiple Myeloma: A Real-Life Monocentric Italian Experience [PDF]

, 2023
Francesca Fazio, Mauro Passucci, Jacopo Micozzi, Silvia Sorella, Chiara Lisi, David Fanciullo, Alfonso Piciocchi, Mahnaz Shafii Bafti, Maurizio Martelli, Maria Gozzer, Maria Teresa Petrucci   +10 more
openalex   +1 more source

Mechanisms of action and clinical development of elotuzumab [PDF]

, 2017
Colonna, Marco, Ritchie, David
core   +2 more sources

Optimizing treatment sequencing in multiple myeloma: a novel model to predict survival outcomes [PDF]

Over the past few years, many new treatments have been approved for patients with multiple myeloma (MM) and these have improved outcomes like response rates and survival.
Armeni, Patrizio, Bringhen, Sara, Entrala Cerezo, Cristina, Mendes, João, Petrucci, Maria Teresa   +4 more
core   +1 more source

Real-world drug regimes for multiple myeloma in a Swiss population (2012 to 2017) : cost-outcome description [PDF]

, 2019
Blozik, Eva, Eichler, Klaus, Rapold, Ronald, Reich, Oliver, Wieser, Simon   +4 more
core   +1 more source

An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers

Advanced Science
First‐line treatment of multiple myeloma, a prevalent blood cancer lacking a cure, using anti‐CD38 daratumumab antibody and lenalidomide is often inadequate due to relapse and severe side effects.
Yueh‐Hsiang Yu, Wei‐Ting Tian, Cédric Grauffel, Wei‐Chen Lin, Ming‐Yu Hsieh, Pei‐Wen Wu, Hui‐Ju Lee, Chi‐Jiun Peng, Pei‐Hsuan Lin, Hsing‐Mao Chu, Carmay Lim, Tse Wen Chang   +11 more
doaj   +1 more source

Supplementary Data from Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma

, 2023
Hyunsoo Cho, Kyung Hwan Kim, Hoyoung Lee, Chang Gon Kim, Haerim Chung, Yoon Seok Choi, Su‐Hyung Park, June‐Won Cheong, Yoo Hong Min, Eui‐Cheol Shin, Jin Seok Kim   +10 more
openalex   +1 more source